


Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. **(previously presented)** A compound in the form of an enantiomer (1*R*,2*R*) or (1*S*,2*S*) or in the form of a threo diastereoisomer, corresponding to general formula (I)



in which A represents

a group of general formula N-R₁, a group of general formula N⁺(O⁻)R₁ or a group of general formula N⁺(R')R₁, and in which R₁ represents either a hydrogen atom, or a linear or branched (C₁-C₇)alkyl group optionally substituted with one or more fluorine atoms, or a (C₄-C₇)cycloalkyl group, or a (C₃-C₇)cycloalkyl(C₁-C₃)alkyl group, or a phenyl(C₁-C₃)alkyl group optionally substituted with one or two hydroxyl or methoxy groups, or a (C₂-C₄)alkenyl group, or a (C₂-C₄)alkynyl group,

R' represents a linear or branched (C₁-C₇)alkyl group,

X represents a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromethyl, linear or branched (C₁-C₄)alkyl and (C₁-C₄)alkoxy groups,

R₂ represents either a hydrogen atom, or one or more substituents chosen from halogen atoms and trifluoromethyl, (C₁-C₄)alkyl or (C₁-C₄)alkoxy groups, or amino groups of general formula NR₃R₄ in which R₃ and R₄ each represent, independently of each other, a hydrogen atom or a (C₁-C₄)alkyl group, or form with the nitrogen atom carrying them a pyrrolidine, piperidine or morpholine ring, or a phenyl group optionally substituted with an atom or a group as defined for the symbol X above,

in the form of a free base or of an addition salt with an acid.

2. **(previously presented)** A compound according to Claim 1 wherein it has the configuration (1*S*,2*S*) and in that R₂ represents one or more halogen atoms or trifluoromethyl groups.
3. **(previously presented)** A compound according to Claim 1 wherein it has the configuration (1*R*,2*R*) and in that R₂ represents a halogen atom and an amino group of general formula NR₃R₄ as defined in Claim 1.
4. **(cancelled)**
5. **(previously presented)** A pharmaceutical composition comprising a compound according to Claim 1 combined with an excipient.
6. **(original)** 2-Chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide according to claim 1.
7. **(original)** 2-Chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide hydrochloride 1:1 according to claim 6.
8. **(original)** A pharmaceutical composition comprising a compound according to Claim 2 combined with an excipient.
9. **(original)** A pharmaceutical composition comprising a compound according to Claim 3 combined with an excipient.
10. **(original)** A pharmaceutical composition comprising a compound according to Claim 6 combined with an excipient.

11. **(original)** A pharmaceutical composition comprising a compound according to Claim 7 combined with an excipient.

12. - 16. **(cancelled)**

17. **(original)** A compound according to claim 1 wherein A represents a group of general formula N-R₁ in which R₁ represents either a hydrogen atom, or a linear or branched (C₁-C₇)alkyl group optionally substituted with one or more fluorine atoms and said compound in the form of a free base or of an addition salt with an acid.

18. **(original)** A compound according to claim 1 which is selected from the group consisting of:

- threo-2-chloro-*N*-[(1-ethylpiperidin-2-yl)phenylmethyl]-3-trifluoromethylbenzamide hydrochloride;
- threo-2-chloro-*N*-[(1-ethylpiperidin-2-yl)phenylmethyl]-3-trifluoromethylbenzamide;
- 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethylbenzamide hydrochloride;
- 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethylbenzamide;
- threo-4-amino-3-chloro-*N*-[(1-methylpiperidin-2-yl)phenylmethyl]-5-trifluoromethylbenzamide hydrochloride;
- threo-4-amino-3-chloro-*N*-[(1-methylpiperidin-2-yl)phenylmethyl]-5-trifluoromethylbenzamide;
- 4-amino-3-chloro-*N*-[(1*R*)-[(2*R*)-1-methylpiperidin-2-yl]phenylmethyl]-5-trifluoromethylbenzamide hydrochloride;

- 4-amino-3-chloro-*N*-[(1*R*)-[(2*R*)-1-methylpiperidin-2-yl]phenylmethyl]-5-trifluoromethylbenzamide;
- threo-2-chloro-*N*-[phenyl(piperidin-2-yl)methyl]-3-trifluoromethylbenzamide hydrochloride;
- threo-2-chloro-*N*-[phenyl(piperidin-2-yl)methyl]-3-trifluoromethylbenzamide;
- 2-chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide hydrochloride;
- 2-chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide;
- 2-chloro-*N*-[[1-methyl-1-oxido-piperidin-2-yl](phenyl)methyl]-3-trifluoromethylbenzamide; and
- 2(*S*)-2[(1*S*)-[[2-chloro-3-(trifluoromethyl)benzoyl]amino](phenyl)methyl]-1,1-dimethylpiperidinium iodide or
a pharmaceutically acceptable salt thereof.

19. **(original)** 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethylbenzamide according to claim 1.

20. **(original)** 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethylbenzamide hydrochloride 1:1 according to claim 1.

21. **(original)** 4-amino-3-chloro-*N*-[(1*R*)-[(2*R*)-1-methylpiperidin-2-yl]phenylmethyl]-5-trifluoromethylbenzamide hydrochloride 1:1 according to claim 1.

22. **(original)** A pharmaceutical composition comprising a compound according to Claim 18 combined with an excipient.

23. **(original)** A pharmaceutical composition comprising a compound according to Claim 19 combined with an excipient.

24. **(original)** A pharmaceutical composition comprising a compound according to Claim 20 combined with an excipient.

25. **(original)** A pharmaceutical composition comprising a compound according to Claim 21 combined with an excipient.

26. **(currently amended)** A method for the treatment of a ~~disorder associated with glytl~~
~~glycine transporter~~ disorder selected from the group consisting of dementia, psychoses,
schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks,
depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising
administering to a patient in need of said treatment an effective amount of a compound
according to Claim 1.

27. **(currently amended)** A method for the treatment of a ~~disorder associated with glytl~~
~~glycine transporter~~ disorder selected from the group consisting of dementia, psychoses,
schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks,
depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising
administering to a patient in need of said treatment an effective amount of a compound
according to Claim 2.

28. **(currently amended)** A method for the treatment of a ~~disorder associated with glytl~~
~~glycine transporter~~ disorder selected from the group consisting of dementia, psychoses,
schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks,
depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising
administering to a patient in need of said treatment an effective amount of a compound
according to Claim 6.

29. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1~~
~~glycine transporter~~ disorder selected from the group consisting of dementia, psychoses,
schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks,
depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising
administering to a patient in need of said treatment an effective amount of a compound
according to Claim 7.

30. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1~~
~~glycine transporter~~ disorder selected from the group consisting of dementia, psychoses,
schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks,
depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising
administering to a patient in need of said treatment an effective amount of a compound
according to Claim 17.

31. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1~~
~~glycine transporter~~ disorder selected from the group consisting of dementia, psychoses,
schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks,
depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising
administering to a patient in need of said treatment an effective amount of a compound
according to Claim 18.

32. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1~~
~~glycine transporter~~ disorder selected from the group consisting of dementia, psychoses,
schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks,
depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising
administering to a patient in need of said treatment an effective amount of a compound
according to Claim 19.

33. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt1~~
~~glycine transporter~~ disorder selected from the group consisting of dementia, psychoses,
schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks,
depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising
administering to a patient in need of said treatment an effective amount of a compound
according to Claim 20.

34. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt2~~
~~glycine transporter~~ disorder selected from the group consisting of painful muscular
contractures in rheumatology, spinal pathology, pain including neurogenic pain,
rebellious algia, Parkinson's disease, epilepsy and sleep apnea, comprising administering
to a patient in need of said treatment an effective amount of a compound according to
Claim 1.

35. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt2~~
~~glycine transporter~~ disorder selected from the group consisting of painful muscular
contractures in rheumatology, spinal pathology, pain including neurogenic pain,
rebellious algia, Parkinson's disease, epilepsy and sleep apnea, comprising administering
to a patient in need of said treatment an effective amount of a compound according to
Claim 3.

36. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt2~~
~~glycine transporter~~ disorder selected from the group consisting of painful muscular
contractures in rheumatology, spinal pathology, pain including neurogenic pain,
rebellious algia, Parkinson's disease, epilepsy and sleep apnea, comprising administering
to a patient in need of said treatment an effective amount of a compound according to
Claim 17.

37. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt2 glycine transporter~~ disorder selected from the group consisting of painful muscular contractures in rheumatology, spinal pathology, pain including neurogenic pain, rebellious algia, Parkinson's disease, epilepsy and sleep apnea, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 18.

38. **(currently amended)** A method for the treatment of a ~~disorder associated with glyt2 glycine transporter~~ disorder selected from the group consisting of painful muscular contractures in rheumatology, spinal pathology, pain including neurogenic pain, rebellious algia, Parkinson's disease, epilepsy and sleep apnea, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 21.